## Translational Program Grant Final Report

Due: **3 months after the grant end date**

### Section A – Project Identification

#### A.1 Project Information

|  |  |
| --- | --- |
| Grant ID No. |  |
| Project Title |  |
| Chief Investigator Full Name |  |
| Email Address |  |
| ORCID (required) |  |
| Administering Institution |  |
| Facilitating Institution/Employing Institute |  |
| Funding Commencement Date |  |
| Funding End Date |  |

### Section B – Project Summary, Achievements and Impact

B.1.1 Target populations

Please indicate if this Grant targeted any of the following populations and/or communities.

|  |  |  |  |
| --- | --- | --- | --- |
| Population/ Community | Yes/No | Population/ Community | Yes/No |
| Aboriginal communities  |  | Children |  |
| Multicultural communities |  | Older people (65+ years) |  |
| Adolescents and young adults |  | People with a mental health condition   |  |
| Regional, rural, and remote communities  |  | Sexuality and gender diverse people (lesbian, gay, bisexual, transgender, intersex and queer people, known as LGBTIQ+ communities)  |  |
| People from lower socioeconomic backgrounds  |  | People who are engaged with the justice system.  |  |

B.1.2 Project Summary

Did this Grant involve the use of animals?

[ ]  Yes [ ]  No

If yes, please provide further detail.

|  |
| --- |
|  |

#### B.1.3 Project Summary

Please include the original lay summary from your application.

|  |
| --- |
|  |

#### B.2 Research Plan

Please summarise your research plan and objectives as per the original application ***(250 words max).***

|  |
| --- |
|  |

#### B.3 Research Progress against Stated Objectives

Were all the objectives of the grant met?

[ ]  Yes [ ]  No

#### B.4 Research Progress

For the entire duration of the grant, please outline progress of your research against your stated research plan explaining how you have met the objectives and intended outcomes of the project as specified in section B.2. If any objective of the grant was not met, please provide justification detailing why the objective was not met (suggested length approx. 800-1000 words).

|  |
| --- |
|  |

### Section C – Research Achievements and Outputs

Please nominate the stages of the Model of Translational Research that this grant was targeting. *Please refer to Appendix 1 for T1, T2 and T3 information.*

[ ]  T1- Translation to Humans/ Basic Research *(Observational Studies, Case Studies, Phase I and II Clinical Trials)*

[ ]  T2- Translation to Patients, Policy and Practice/ Human Clinical Research *(Controlled Observational Studies, Phase III Clinical Trials, Survey Research, Guideline Development)*

[ ]  T3- Translation to Policy and Practice/ Clinical Practice across the system *(Phase IV Clinical Trials, Dissemination, Implementation, Diffusion)*

|  |
| --- |
|  |

#### C.1 Research Achievements

Please describe in ***lay terms***, at least three of your most significant research achievements that have occurred as a result of this grant. These achievements should be written in language suitable for the general public and should outline what the problem was, what the research/grant achieved and why this is important. *(Insert tables as required)*

*Please note that this information may be made available to the general public on the* *Cancer Institute NSW website or any other materials for promotional purposes.*

|  |
| --- |
| **Description of Achievement (300 words max)** |
|  |
| **Stage(s) of Translation** | T1 [ ]  | T2 [ ]  | T3 [ ]  |
| **Please choose the categories that best describe this achievement:** |
| Increased the capacity to do further research |  |
| Produced new knowledge |  |
| Developed new diagnostic tools or new therapies |  |
| Informed policy or practice |  |
| Improved health outcomes |  |
| Other - please describe: |  |
| **Who will this achievement most directly impact? (Select all that apply)** |
| Patients/Families |  |
| Clinicians |  |
| Public/Communities |  |
| Other Researchers |  |
| Other - please describe: |  |

|  |
| --- |
| **Description of Achievement (300 words max)** |
|  |
| **Stage(s) of Translation** | T1 [ ]  | T2 [ ]  | T3 [ ]  |
| **Please choose the categories that best describe this achievement:** |
| Increased the capacity to do further research |  |
| Produced new knowledge |  |
| Developed new diagnostic tools or new therapies |  |
| Informed policy or practice |  |
| Improved health outcomes |  |
| Other - please describe: |  |
| **Who will this achievement most directly impact? (Select all that apply)** |
| Patients/Families |  |
| Clinicians |  |
| Public/Communities |  |
| Other Researchers |  |
| Other - please describe: |  |

|  |
| --- |
| **Description of Achievement (300 words max) (Select all that apply)** |
|  |
| **Stage(s) of Translation** | T1 [ ]  | T2 [ ]  | T3 [ ]  |
| **Please choose the categories that best describe this achievement:** |
| Increased the capacity to do further research |  |
| Produced new knowledge |  |
| Developed new diagnostic tools or new therapies |  |
| Informed policy or practice |  |
| Improved health outcomes |  |
| Other - please describe: |  |
| **Who will this achievement most directly impact?** |
| Patients/Families |  |
| Clinicians |  |
| Public/Communities |  |
| Other Researchers |  |
| Other - please describe: |  |

#### C.2 How has this Translational Program Grant strengthened cancer research collaborations, networks and/or consortia to provide greater research depth? ***(150 words max).***

|  |
| --- |
|  |

#### C.3 How has this Translational Program Grant increased research capacity and activity to address pressing clinical problems, in ways which would not have occurred otherwise? ***(150 words max).***

|  |
| --- |
|  |

#### C.4 How has this Translational Program Grant delivered world-class translational cancer research at the highest standards? ***(150 words max).***

|  |
| --- |
|  |

#### C.5 Is there any interest in commercialising your research? If so, please provide details ***(150 words max)***.

|  |
| --- |
|  |

#### C.6 Message of Impact for Cancer Research

Please describe the impact this Translational Program Grant has had for cancer researchin terms of driving rapid improvements in cancer prevention, treatment, survival and/or quality of life for cancer patients in NSW. Will this research continue following the completion of this TPG? ***(500 words max).***

|  |
| --- |
|  |

### Section D – Research Outputs

Use the Excel template provided to enter ALL research outputs, related to this grant. Research outputs include publications, presentations, leveraged funding and initiation of clinical trials.

### Section E – Workforce Capacity Building

#### E.1 Full Time Equivalent (FTE) staff

Provide a summary of the FTE staff employed through this program over the life of the grant.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Year 1** | **Year 2** | **Year 3** | **Year 4** | **Year 5** |
| Researchers (include Post-doctoral, Research Fellows, Senior Scientists) |  |  |  |  |  |
| Clinicians/Clinical Fellows |  |  |  |  |  |
| Research support staff (include RAs, Project Officers, Technical staff) |  |  |  |  |  |
| Nurse/Data managers |  |  |  |  |  |
| Program/Research Managers |  |  |  |  |  |
| Other (please describe) |  |  |  |  |  |
| **Total FTE** |  |  |  |  |  |

#### E.2 Higher Degree Research Students

Provide the number of any higher degree research students who have been supported by the funded personnel (through either supervision or use of supported infrastructure).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Type | NumberEnrolled | Number Completed | Number with Stipend or Scholarship from this program grant | Student’s destination following conclusion of their HDR study\* |
| PhD |  |  |  |  |
| Masters (Research) |  |  |  |  |
| Honours |  |  |  |  |
| Other (please describe)  |  |  |  |  |

\*Employed in cancer research via a Federal/State/Institutional/Organisational/Other funding, Employed in non-cancer research, Not continuing a research career, Other (please specify), Unknown at this time.

Please provide additional information for the PhD students.

|  |  |  |  |
| --- | --- | --- | --- |
| PhD Student Full Name | ORCID  | PhD Commencement Date | PhD Completion Date |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

### Section F – Case Studies

Provide at least one case study **using the template provided.**

### Section G – Additional information

List any additional documents that are included with this report.

|  |
| --- |
| Document Name |
| Research Outputs Spreadsheet |
| Case Study |

### Section H – Certification

#### H.1 Certification by Chief Investigator

I certify that this is an accurate report for the period covered.

|  |  |
| --- | --- |
| Name |  |
| Date |  |
| Signature |  |

#### H.2 Certification by Administering Institution Director

I certify that this is an accurate report for the period covered.

|  |  |
| --- | --- |
| Name |  |
| Date |  |
| Signature |  |

### Submission

* The Chief Investigator must complete this report, as well as the *Research Outputs Spreadsheet, and one Case Study* and send to the Administering Institution for certification.
* The Administering Institution is responsible for the accurate submission of completed and certified report form.
* Section H must be signed by the Chief Investigator and Administering Institution Director. Electronic signatures are acceptable.
* Note: *Late submissions of reports may affect eligibility for future funding.*

### APPENDIX 1: CANCER INSTITUTE NSW MODEL OF TRANSLATION

Figure 1 below is the model of translational research used by the Cancer Institute NSW. This model focuses on the translation of basic research into clinical research as well as being applicable to the translation of population health and health services research informing programs and service delivery.

Figure 1 outlines /classifies the stages of translational research as:

* **T1**- developing treatments and interventions.
* **T2** - testing the efficacy and effectiveness of these treatments and interventions.
* **T3** - dissemination and implementation research for system-wide change.

**Figure 1:** Model of Translational Research



Westfall et al., (2007). Practice-based research – “blue highways” on NIH roadmap. JAMA, 297(4): 403-406 (adaptation)

NSW Health and Medical Research Strategic Review 2012—page 4 (adaption)

### Detailed Translational Pipeline Definitions:

#### T1 - Translation to Humans

* Developing treatments and interventions
* The translation of basic research into research with humans. Basic research could cover a range of disciplines including, laboratory research, epidemiology, psychometrics, social science.
* The interface between basic research and the clinical setting, striving to find how new knowledge of disease mechanisms can be developed into clinically relevant understandings, and diagnostic and treatment regimes to be trialled in humans.
* Types of studies/activities – Observational studies, Case studies; Phase 1 and II clinical trials

#### T2 - Translation to Patients

* Testing the efficacy and effectiveness of these treatments and interventions.
* The translation of new clinical science and knowledge into routine clinical practice and health decision making[[1]](#footnote-2). Translation of new clinically proven knowledge of disease processes, diagnostic or treatment techniques into routine clinical practice and health decision making.
* Types of studies/activities - Phase III clinical trials; observational studies; evidence synthesis and guidelines development.

#### T3 - Translation to Practice

* Dissemination and implementation research for system-wide change2.
* The application of information and insights derived from basic, clinical and population health research to the provision of health services[[2]](#footnote-3).
* Moving evidence-based guidelines into health practice, through delivery, dissemination, and diffusion research.
* Practice based research, where the evidence from clinical trials on carefully selected patients is translated into guidelines for patients seen routinely in practice.
* Types of studies/activities - Dissemination research; implementation research; diffusion research, Phase IV clinical trials.
1. Grimshaw et al, 2012 [↑](#footnote-ref-2)
2. Wills NSW Health and Medical Research Strategic Review [↑](#footnote-ref-3)